The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Bipolar Disorder-Global Market Insights and Sales Trends 2025
Synopsis
Bipolar disorder (formerly called manic-depressive illness or manic depression) is a mental disorder that causes unusual shifts in mood, energy, activity levels, concentration, and the ability to carry out day-to-day tasks.
The global Bipolar Disorder market size is expected to reach US$ 6994.7 million by 2029, growing at a CAGR of 2.7% from 2023 to 2029. The market is mainly driven by the significant applications of Bipolar Disorder in various end use industries. The expanding demands from the Mood Stabilizers, Anticonvulsants, Antipsychotic drugs and Antidepressant drugs, are propelling Bipolar Disorder market. Bipolar I Disorder, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Bipolar II Disorder segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Bipolar Disorder market, driven by demand from China, the second largest economy with some signs of stabilising, the Bipolar Disorder market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Bipolar Disorder, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Bipolar Disorder market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Bipolar Disorder market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Bipolar Disorder sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Bipolar Disorder covered in this report include Glaxo SmithKline (GSK), Pfizer Inc., Janssen Pharmaceuticals, Eli Lilly, Allergan Plc., Novartis AG, AbbVie Inc., Otsuka Holdings Ltd and AstraZeneca, etc.
The global Bipolar Disorder market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Glaxo SmithKline (GSK)
Pfizer Inc.
Janssen Pharmaceuticals
Eli Lilly
Allergan Plc.
Novartis AG
AbbVie Inc.
Otsuka Holdings Ltd
AstraZeneca
Global Bipolar Disorder market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Bipolar Disorder market, Segment by Type:
Bipolar I Disorder
Bipolar II Disorder
Cyclothymic Disorder
Global Bipolar Disorder market, by Application
Mood Stabilizers
Anticonvulsants
Antipsychotic drugs
Antidepressant drugs
Antianxiety drugs
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Bipolar Disorder companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Bipolar disorder (formerly called manic-depressive illness or manic depression) is a mental disorder that causes unusual shifts in mood, energy, activity levels, concentration, and the ability to carry out day-to-day tasks.
The global Bipolar Disorder market size is expected to reach US$ 6994.7 million by 2029, growing at a CAGR of 2.7% from 2023 to 2029. The market is mainly driven by the significant applications of Bipolar Disorder in various end use industries. The expanding demands from the Mood Stabilizers, Anticonvulsants, Antipsychotic drugs and Antidepressant drugs, are propelling Bipolar Disorder market. Bipolar I Disorder, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Bipolar II Disorder segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Bipolar Disorder market, driven by demand from China, the second largest economy with some signs of stabilising, the Bipolar Disorder market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Bipolar Disorder, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Bipolar Disorder market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Bipolar Disorder market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Bipolar Disorder sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Bipolar Disorder covered in this report include Glaxo SmithKline (GSK), Pfizer Inc., Janssen Pharmaceuticals, Eli Lilly, Allergan Plc., Novartis AG, AbbVie Inc., Otsuka Holdings Ltd and AstraZeneca, etc.
The global Bipolar Disorder market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Glaxo SmithKline (GSK)
Pfizer Inc.
Janssen Pharmaceuticals
Eli Lilly
Allergan Plc.
Novartis AG
AbbVie Inc.
Otsuka Holdings Ltd
AstraZeneca
Global Bipolar Disorder market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Bipolar Disorder market, Segment by Type:
Bipolar I Disorder
Bipolar II Disorder
Cyclothymic Disorder
Global Bipolar Disorder market, by Application
Mood Stabilizers
Anticonvulsants
Antipsychotic drugs
Antidepressant drugs
Antianxiety drugs
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Bipolar Disorder companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Bipolar Disorder
1.1 Bipolar Disorder Market Overview
1.1.1 Bipolar Disorder Product Scope
1.1.2 Bipolar Disorder Market Status and Outlook
1.2 Global Bipolar Disorder Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Bipolar Disorder Market Size by Region (2018-2029)
1.4 Global Bipolar Disorder Historic Market Size by Region (2018-2023)
1.5 Global Bipolar Disorder Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Bipolar Disorder Market Size (2018-2029)
1.6.1 North America Bipolar Disorder Market Size (2018-2029)
1.6.2 Europe Bipolar Disorder Market Size (2018-2029)
1.6.3 Asia-Pacific Bipolar Disorder Market Size (2018-2029)
1.6.4 Latin America Bipolar Disorder Market Size (2018-2029)
1.6.5 Middle East & Africa Bipolar Disorder Market Size (2018-2029)
2 Bipolar Disorder Market by Type
2.1 Introduction
2.1.1 Bipolar I Disorder
2.1.2 Bipolar II Disorder
2.1.3 Cyclothymic Disorder
2.2 Global Bipolar Disorder Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Bipolar Disorder Historic Market Size by Type (2018-2023)
2.2.2 Global Bipolar Disorder Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Bipolar Disorder Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Bipolar Disorder Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Bipolar Disorder Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Bipolar Disorder Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Bipolar Disorder Revenue Breakdown by Type (2018-2029)
3 Bipolar Disorder Market Overview by Application
3.1 Introduction
3.1.1 Mood Stabilizers
3.1.2 Anticonvulsants
3.1.3 Antipsychotic drugs
3.1.4 Antidepressant drugs
3.1.5 Antianxiety drugs
3.1.6 Others
3.2 Global Bipolar Disorder Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Bipolar Disorder Historic Market Size by Application (2018-2023)
3.2.2 Global Bipolar Disorder Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Bipolar Disorder Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Bipolar Disorder Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Bipolar Disorder Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Bipolar Disorder Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Bipolar Disorder Revenue Breakdown by Application (2018-2029)
4 Bipolar Disorder Competition Analysis by Players
4.1 Global Bipolar Disorder Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Bipolar Disorder as of 2022)
4.3 Date of Key Players Enter into Bipolar Disorder Market
4.4 Global Top Players Bipolar Disorder Headquarters and Area Served
4.5 Key Players Bipolar Disorder Product Solution and Service
4.6 Competitive Status
4.6.1 Bipolar Disorder Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Glaxo SmithKline (GSK)
5.1.1 Glaxo SmithKline (GSK) Profile
5.1.2 Glaxo SmithKline (GSK) Main Business
5.1.3 Glaxo SmithKline (GSK) Bipolar Disorder Products, Services and Solutions
5.1.4 Glaxo SmithKline (GSK) Bipolar Disorder Revenue (US$ Million) & (2018-2023)
5.1.5 Glaxo SmithKline (GSK) Recent Developments
5.2 Pfizer Inc.
5.2.1 Pfizer Inc. Profile
5.2.2 Pfizer Inc. Main Business
5.2.3 Pfizer Inc. Bipolar Disorder Products, Services and Solutions
5.2.4 Pfizer Inc. Bipolar Disorder Revenue (US$ Million) & (2018-2023)
5.2.5 Pfizer Inc. Recent Developments
5.3 Janssen Pharmaceuticals
5.3.1 Janssen Pharmaceuticals Profile
5.3.2 Janssen Pharmaceuticals Main Business
5.3.3 Janssen Pharmaceuticals Bipolar Disorder Products, Services and Solutions
5.3.4 Janssen Pharmaceuticals Bipolar Disorder Revenue (US$ Million) & (2018-2023)
5.3.5 Eli Lilly Recent Developments
5.4 Eli Lilly
5.4.1 Eli Lilly Profile
5.4.2 Eli Lilly Main Business
5.4.3 Eli Lilly Bipolar Disorder Products, Services and Solutions
5.4.4 Eli Lilly Bipolar Disorder Revenue (US$ Million) & (2018-2023)
5.4.5 Eli Lilly Recent Developments
5.5 Allergan Plc.
5.5.1 Allergan Plc. Profile
5.5.2 Allergan Plc. Main Business
5.5.3 Allergan Plc. Bipolar Disorder Products, Services and Solutions
5.5.4 Allergan Plc. Bipolar Disorder Revenue (US$ Million) & (2018-2023)
5.5.5 Allergan Plc. Recent Developments
5.6 Novartis AG
5.6.1 Novartis AG Profile
5.6.2 Novartis AG Main Business
5.6.3 Novartis AG Bipolar Disorder Products, Services and Solutions
5.6.4 Novartis AG Bipolar Disorder Revenue (US$ Million) & (2018-2023)
5.6.5 Novartis AG Recent Developments
5.7 AbbVie Inc.
5.7.1 AbbVie Inc. Profile
5.7.2 AbbVie Inc. Main Business
5.7.3 AbbVie Inc. Bipolar Disorder Products, Services and Solutions
5.7.4 AbbVie Inc. Bipolar Disorder Revenue (US$ Million) & (2018-2023)
5.7.5 AbbVie Inc. Recent Developments
5.8 Otsuka Holdings Ltd
5.8.1 Otsuka Holdings Ltd Profile
5.8.2 Otsuka Holdings Ltd Main Business
5.8.3 Otsuka Holdings Ltd Bipolar Disorder Products, Services and Solutions
5.8.4 Otsuka Holdings Ltd Bipolar Disorder Revenue (US$ Million) & (2018-2023)
5.8.5 Otsuka Holdings Ltd Recent Developments
5.9 AstraZeneca
5.9.1 AstraZeneca Profile
5.9.2 AstraZeneca Main Business
5.9.3 AstraZeneca Bipolar Disorder Products, Services and Solutions
5.9.4 AstraZeneca Bipolar Disorder Revenue (US$ Million) & (2018-2023)
5.9.5 AstraZeneca Recent Developments
6 North America
6.1 North America Bipolar Disorder Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Bipolar Disorder Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Bipolar Disorder Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Bipolar Disorder Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Bipolar Disorder Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Bipolar Disorder Market Dynamics
11.1 Bipolar Disorder Industry Trends
11.2 Bipolar Disorder Market Drivers
11.3 Bipolar Disorder Market Challenges
11.4 Bipolar Disorder Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
